VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
NVONovo Nordisk A/S
$43.19$191.9B
Research
OverviewAnalysisShould I Buy?
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksNVOPrice Target
NVO logo

Novo Nordisk A/S (NVO) Price Target Analysis

Updated Jun 18, 2026
Analyst Rating: Buy
Based on 39 analysts

4.2% Below Target

NVO trades 4.2% below Wall Street's consensus target of $45.00.

Current Price$43.19
Average Target$45.00
Low$45.00
Median$45.00
High$45.00

Analyst Target Range

Forward P/E2.0x
(Value)
PEG Ratio0.10
(Undervalued)
Implied Growth-21.2%
(Declining)
Analyst Spread0.0%
(High Agreement)

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$43.19
Consensus$45.00
High$45.00
Low$45.00

Consensus Scenario Assumptions

The base valuation assumes NVO achieves its forward estimates and maintains a stable P/E multiple of 2.0x. This scenario reflects the blended consensus of 39 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.

Analyst Ratings Distribution

Breakdown of 39 published analyst recommendations for NVO

33% hold / mixed conviction
+27
BearishBullish
Weighted analyst sentiment score based on 39 ratings
ConsensusBuy
Coverage39 Analysts
Net Score+27
Bull / Bear59% / 8%
Strong Buy13%
Buy2256%
Hold1333%
Sell38%
Strong Sell00%
Strong Buy
13%
Buy
2256%
Hold
1333%
Sell
38%
Strong Sell
00%
Recommendation Mix59% Buy · 33% Hold · 8% Sell
Buy (23)Hold (13)Sell (3)

NVO Price Target Analysis

Updated June 22, 2026

As of June 22, 2026, Novo Nordisk A/S (NVO) has a Wall Street consensus price target of $45.00, based on estimates from 39 covering analysts. With the stock currently trading at $43.19, this represents a potential upside of +4.2%. The company has a market capitalization of $191.93B.

Analyst price targets range from a low of $45.00 to a high of $45.00, representing a 0% spread in expectations. The median target of $45.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.

The current analyst consensus rating is Buy, with 23 analysts rating the stock as a Buy or Strong Buy,13 rating it Hold, and 3 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.

From a valuation perspective, NVO trades at a trailing P/E of 12.2x and forward P/E of 2.0x. The forward PEG ratio of 0.10 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow -21.2% over the next year.

Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $335.48, with bear and bull scenarios of $211.35 and $442.03 respectively. Model confidence stands at 63/100, reflecting moderate uncertainty in projections.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside
+11.7%
Industry Consensus
Avg Forward P/E
19.3x
(Fair)
Peers with Coverage
10 / 10
Active Analyst Tracking
CompanyMarket CapPriceTargetUpside PotentialRatingFwd P/EAnalysts
LLY logo
LLYEli Lilly and Company
$1.0T$1098.13$1271.24
+15.8%
Buy30.0x45
SNY logo
SNYSanofi
$102.4B$42.38$51.00
+20.3%
Buy10.1x27
AZN logo
AZNAstraZeneca PLC
$271.2B$174.93$186.67
+6.7%
Buy17.0x41
NVS logo
NVSNovartis AG
$280.6B$147.08$170.00
+15.6%
Hold16.9x25
ROG logo
ROGRogers Corporation
$2.9B$162.68$150.00
-7.8%
Buy44.7x12
MRK logo
MRKMerck & Co., Inc.
$281.2B$113.87$131.58
+15.6%
Buy22.2x37
PFE logo
PFEPfizer Inc.
$143.5B$25.22$26.75
+6.1%
Hold8.5x39
BMY logo
BMYBristol-Myers Squibb Company
$110.3B$54.00$62.60
+15.9%
Hold8.5x41
ABBV logo
ABBVAbbVie Inc.
$383.2B$216.63$256.92
+18.6%
Buy15.2x41
JNJ logo
JNJJohnson & Johnson
$550.4B$228.39$251.55
+10.1%
Buy19.7x40

NVO — Frequently Asked Questions

Quick answers to the most common questions about buying NVO stock.

What is the NVO stock price target for 2026?

The consensus price target for NVO is $45, close to the current price of $43.19 (4.2% implied move). Based on 39 analyst estimates, the stock appears fairly valued near current levels.

Is NVO a buy, sell, or hold?

NVO has a consensus rating of "Buy" based on 39 Wall Street analysts. The rating breakdown is predominantly bullish, with 23 Buy/Strong Buy ratings. The consensus 12-month price target of $45 implies 4.2% upside from current levels.

Is NVO stock overvalued or undervalued?

With a forward P/E of 1.9987x, NVO trades at a relatively low valuation. The consensus target of $45 implies 4.2% appreciation, suggesting the market may be pricing in risks.

How high can NVO stock go?

The most bullish Wall Street analyst has a price target of $45 for NVO, while the most conservative target is $45. The consensus of $45 represents the median expectation. Our quantitative valuation model projects a bull case target of $442 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

How many analysts cover NVO stock?

NVO is heavily covered by Wall Street, with 39 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 22 have Buy ratings, 13 recommend Hold, and 3 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the NVO stock forecast?

The 12-month NVO stock forecast based on 39 Wall Street analysts shows a consensus price target of $45, with estimates ranging from $45 (bear case) to $45 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $335, with bear/bull scenarios of $211/$442.

What is NVO's fair value based on fundamentals?

Our quantitative valuation model calculates NVO's fair value at $335 (base case), with a bear case of $211 and bull case of $442. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 63/100.

What is NVO's forward P/E ratio?

NVO trades at a forward P/E ratio of 2.0x based on next-twelve-months earnings estimates compared to a trailing P/E of 12.2x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Should I buy NVO stock?

NVO appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $45 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do NVO price targets vary so much?

NVO analyst price targets range from $45 to $45, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $45 consensus represents the middle ground. Our model's $211-$442 range provides an independent fundamental perspective.

Consensus-Based Analysis Tools

Full Stock Analysis

Deep dive into NVO consensus models and risk factors.

View Analysis

Should I Buy NVO?

Wall Street verdict, signals, and target summaries.

See Verdict

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare